10:26 AM EDT, 10/16/2024 (MT Newswires) -- Corbus Pharmaceuticals ( CRBP ) said Wednesday it has completed enrollment of the dose escalation part of its bridging phase 1 clinical trial of CRB-701 to evaluate its safety and efficacy in patients with advanced solid tumors related to high Nectin-4 expression.

The study's dose escalation part is evaluating four predetermined doses, to be followed by a dose optimization part and a dose expansion part, the company said.

Corbus said the first data from dose escalation is expected in Q1 2025.

Price: 18.78, Change: -0.09, Percent Change: -0.48